On April 29th, 2026, the publication of SECEX Circular No. 32/2026 initiated the sunset review of the anti-dumping duties on Brazilian imports of plastic vacuum blood collection tubes originating from China, the United States of America (USA) and the United Kingdom. The product under investigation is usually classified under subheadings 3822.19.90, 3926.90.40 and 9018.39.99 of the Mercosur Common Nomenclature (NCM).

The anti-dumping duties were originally applied by CAMEX Resolution No. 26, dated April 29, 2015. The measure was extended by GECEX Resolution No. 193, dated April 28, 2021.

The current review was motivated by a petition filed by Greiner Bio-One Brasil Produtos Médicos Hospitalares Ltda. After a preliminary analysis, the Foreign Trade Secretariat (SECEX), through the Department of Trade Remedies (DECOM), recommended the initiation of the sunset review to verify the need for the extension of the anti-dumping duties applied to the mentioned blood collection tubes, in light of evidence suggesting that the termination of the measure would most likely lead to the recurrence of dumping in exports from the investigated origins and the recurrence of injury.

The main information of the process is summarized below:

  • Petitioner: Greiner Bio-One Brasil Produtos Médicos Hospitalares Ltda.
  • Origin: China, USA and United Kingdom.

  • Period of Investigation:

Recurrence of dumping: October 2024 to September 2025.

Recurrence of injury to domestic industry: October 2020 to September 2025.

  • Product under investigation:

Classification: Usually classified in subheadings 19.90, 3926.90.40 and 9018.39.99 of the NCM.

Description: Plastic vacuum blood collection tubes, with diameters ranging from 8 to 16 millimeters, lengths from 45 to 100 millimeters, and draw volumes from 1 to 10 milliliters, with or without a plasma separator, with or without an external safety cap sleeve, regardless of when the vacuum is created, either without additives or containing one or more of the following additives, alone or in combination: ethylenediaminetetraacetic acid (EDTA), clot activator, sodium citrate, sodium heparin, and lithium heparin.

  • Difference between the normal value and the export price for initiation purposes:

China:

Absolute difference: 35,897.97 R$/t.

Relative difference: 68.8%

USA:

Absolute difference: 51,726.15 R$/t.

Relative difference: 99.1%

United Kingdom:

Absolute difference: 57,504.74 R$/t.

Relative difference: 110.2%

The participation of interested parties — including domestic producers, importers, exporters and governments of the countries under investigation — must necessarily be carried out through petitions in the Electronic Information System (SEI) of the Ministry of Development, Industry, Trade and Services (MDIC).

Questionnaires will be sent to the identified interested parties, who will have 30 days from the date of the notification to send their responses. Parties not initially identified at the beginning of the proceeding, but who consider themselves interested may request to be admitted to the case by May 19th, 2026.

The sunset review must be completed within 10 months, extendable for up to 2 additional months. The anti-dumping duties remain in force until the conclusion of the review and, if the initial claims are confirmed, may be renewed for another 5 years.